| Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives S Xiao, Z Tian, Y Wang, L Si, L Zhang, D Zhou Medicinal research reviews 38 (3), 951-976, 2018 | 208 | 2018 |
| Discovery of pentacyclic triterpenoids as potential entry inhibitors of influenza viruses M Yu, L Si, Y Wang, Y Wu, F Yu, P Jiao, Y Shi, H Wang, S Xiao, G Fu, ... Journal of medicinal chemistry 57 (23), 10058-10071, 2014 | 127 | 2014 |
| Synthesis of site-specific radiolabeled antibodies for radioimmunotherapy via genetic code expansion Y Wu, H Zhu, B Zhang, F Liu, J Chen, Y Wang, Y Wang, Z Zhang, L Wu, ... Bioconjugate chemistry 27 (10), 2460-2468, 2016 | 27 | 2016 |
| Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model Y Wang, A Buck, M Grimaud, AC Culhane, S Kodangattil, C Razimbaud, ... Molecular Therapy-Oncolytics 24, 385-399, 2022 | 21 | 2022 |
| Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation Y Wang, X Wu, M Du, X Chen, X Ning, H Chen, S Wang, J Liu, Z Liu, R Li, ... Oncotarget 8 (26), 42510, 2017 | 19 | 2017 |
| Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants MR Chang, H Ke, CD Coherd, Y Wang, K Mashima, GM Kastrunes, ... eBioMedicine 80, 104025, 2022 | 14 | 2022 |
| High‐Throughput Image Cytometry Detection Method for CAR‐T Transduction, Cell Proliferation, and Cytotoxicity Assays Y Wang, LLY Chan, M Grimaud, A Fayed, Q Zhu, WA Marasco Cytometry Part A 99 (7), 689-697, 2021 | 12 | 2021 |
| An unprecedented mixed valence cobalt (III)/cobalt (II) ion-pair complex ([CoCO3 (bipy) 2] 2 [Co (DCA) 2]⋅ 16H2O) with two novel water tapes FL Yin, R Xie, J Hao, YF Wang, JJ Yang Inorganic Chemistry Communications 30, 97-104, 2013 | 10 | 2013 |
| Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells NSP de Campos, A de Oliveira Beserra, PHB Pereira, AS Chaves, ... International Journal of Molecular Sciences 23 (10), 5448, 2022 | 9 | 2022 |
| Develop dual-targeted CAR-T cells to achieve RCC cures Y Wang, M Grimaud, A Buck, A Fayed, M Chang, R Jennings, ... Cancer Research 80 (16_Supplement), 6606-6606, 2020 | 6 | 2020 |
| Evolution of cell therapy for renal cell carcinoma Y Wang, ER Suarez, G Kastrunes, NSP de Campos, R Abbas, RS Pivetta, ... Molecular Cancer 23 (1), 8, 2024 | 5 | 2024 |
| Preclinical models for development of immune–oncology therapies Y Wang, SE Shelton, G Kastrunes, DA Barbie, GJ Freeman, WA Marasco Immuno-oncology insights 3 (8), 379, 2022 | 4 | 2022 |
| Design and activity of 2nd generation, dual-targeted CAR T cell factories against ccRCC Y Wang, ER Suarez, M Chang, R Jennings, S Signoretti, Q Zhu, ... Cancer Research 79 (13_Supplement), 3179-3179, 2019 | 3 | 2019 |
| Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) Y Wang, A Buck, M Grimaud, S Kodangattil, C Razimbaud, A Fayed, ... Cancer Research 81 (13_Supplement), 62-62, 2021 | 2 | 2021 |
| Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects Y Wang, A Buck, B Piel, L Zerefa, N Murugan, CD Coherd, AG Miklosi, ... Molecular Cancer 23 (1), 56, 2024 | 1 | 2024 |
| Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects Y Wang, A Buck, G Kastrunes, R Abbas, M Lynch, Z Zhong, SM Hoang, ... Cancer Research 83 (7_Supplement), 886-886, 2023 | 1 | 2023 |
| 295 Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects Y Wang, A Buck, M Lynch, G Kastrunes, JW Cho, M Grimaud, D Braun, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| Anti-CAIX Immune Restoring (IR) CAR-T cells display superior antitumor activity and reverse immunosuppressive TME in a humanized ccRCC orthotopic mouse model Y Wang, A Buck, M Grimaud, A Culhane, D Braun, S Kodangattil, ... Cancer Research 82 (12_Supplement), 2814-2814, 2022 | 1 | 2022 |
| The Updated Tumor Immune Microenvironment TIME Landscape of Clear Cell Renal Cell Carcinoma ccRCC G Kastrunes, R Abbas, Y Wang, WA Marasco Biomedical Journal of Scientific & Technical Research 44 (3), 35454-35456, 2022 | 1 | 2022 |
| Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy Y Wang Abstracts/Cytotherapy 23, S17-S207, 2021 | 1 | 2021 |
